Tests antineoplaston therapy in certain brainstem glioma patients
Part of Brain & nervous system, Cancer clinical trials.
This Phase 3 trial studies whether antineoplaston therapy changes the heart’s electrical timing (the QT/QTc interval) in people with diffuse intrinsic brainstem glioma. It may be helpful if you’re being evaluated for this specific treatment approach and safety monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be enrolled in the study BRI-BT-52
- If you are not enrolled in BRI-BT-52, you cannot join this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding antineoplaston therapy to standard radiation works better than radiation alone for children and adults with a specific type of brainstem glioma. It aims to improve tumor control while comparing side effects between the two approaches.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This study tests a new way to plan and deliver radiation therapy for glioblastoma (an aggressive brain tumor) using special MRI scans to target cancer cells more precisely. The goal is to improve treatment effectiveness while reducing harm to healthy brain tissue.
This trial tests whether adding sonodynamic therapy (a treatment that uses sound waves to activate a drug) before standard radiation and chemotherapy can help people with a type of brainstem glioma called DIPG. The goal is to see if this combination improves survival.
This trial tests a new type of targeted radiation therapy for people with high-grade glioma (grade 3 or 4) that has not progressed after standard treatment. The therapy uses a radioactive substance attached to a protein that targets tumor cells, aiming to deliver radiation directly to the cancer.
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Hear when a new Brain Stem Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.